Olema Pharmaceuticals logo

Olema Pharmaceuticals Share Price (NASDAQ: OLMA)

$5.45

-0.07

(-1.27%)

Last updated on

Check the interactive Olema Pharmaceuticals Stock chart to analyse performance

Olema Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$5.40
    Today's High:$5.59

    Day's Volatility :3.4%

  • 52 Weeks Low:$2.86
    52 Weeks High:$13.93

    52 Weeks Volatility :79.47%

Olema Pharmaceuticals Stock Returns

PeriodOlema Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
25.03%
3.6%
0.0%
6 Months
29.93%
-7.7%
0.0%
1 Year
-53.64%
-12.6%
0.0%
3 Years
38.48%
9.5%
-4.7%

Olema Pharmaceuticals Inc Key Stats

Check Olema Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$5.52
Open
$5.6
Today's High
$5.59
Today's Low
$5.4
Market Capitalization
$394.0M
Today's Volume
$303.0K
52 Week High
$13.93
52 Week Low
$2.86
Revenue TTM
$0.0
EBITDA
$-151.7M
Earnings Per Share (EPS)
$-1.97
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-49.72%

Stock Returns calculator for Olema Pharmaceuticals Stock including INR - Dollar returns

The Olema Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Olema Pharmaceuticals investment value today

Current value as on today

₹51,471

Returns

₹48,529

(-48.53%)

Returns from Olema Pharmaceuticals Stock

₹53,814 (-53.81%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Olema Pharmaceuticals Stock

50%

Period: Jul 30, 2025 to Aug 29, 2025. Change in 30 Days versus previous period

Search interest for Olema Pharmaceuticals Stock from India on INDmoney has increased by 50% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Olema Pharmaceuticals Inc

  • Name

    Holdings %

  • Bain Capital Life Sciences Investors, LLC

    9.97%

  • Paradigm Biocapital Advisors LP

    9.86%

  • Bvf Inc

    7.72%

  • BlackRock Inc

    5.57%

  • Woodline Partners LP

    5.11%

  • Deep Track Capital, LP

    5.02%

Analyst Recommendation on Olema Pharmaceuticals Stock

Rating
Trend

Buy

    93%Buy

    6%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Olema Pharmaceuticals(by analysts ranked 0 to 5 stars)

Olema Pharmaceuticals Share Price Target

What analysts predicted

Upside of 358.72%

Target:

$25.00

Current:

$5.45

Olema Pharmaceuticals share price target is $25.00, a slight Upside of 358.72% compared to current price of $5.45 as per analysts' prediction.

Olema Pharmaceuticals Stock Insights

  • Price Movement

    In the last 7 days, OLMA stock has moved down by -5.0%
  • OLMA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 123.5%
  • OLMA vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 78.9%

Olema Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Olema Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Olema Pharmaceuticals Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Olema Pharmaceuticals Inc logo
6.42%
29.93%
-53.64%
38.48%
-88.84%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.98%
-0.05%
-6.32%
Beone Medicines Ltd logo
1.77%
24.81%
59.79%
78.52%
26.86%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-21.18%
38.72%
40.03%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
69.91%
115.96%
236.5%

About Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Organization
Olema Pharmaceuticals
Employees
116
CEO
Dr. Sean P. Bohen M.D., Ph.D.
Industry
Health Technology

Key Management of Olema Pharmaceuticals Inc

NameTitle
Dr. Sean P. Bohen M.D., Ph.D.
President, CEO & Director
Mr. Shane William Charles Kovacs M.B.A.
Chief Operating & Financial Officer
Dr. Naseem Zojwalla M.D.
Chief Medical Officer
Ms. Shawnte M. Mitchell J.D.
Chief Legal Officer & Corporate Secretary
Ms. Courtney O'Konek
Vice President of Corporate Communications
Ms. Julie Dexter
Senior VP & Head of People
Dr. David C. Myles Ph.D.
Chief Discovery & Non-Clinical Development Officer
Mr. Richard Hernandez
Senior Vice President of Clinical Development Operations
Dr. Mark Shilkrut M.D., Ph.D.
Senior Vice President of Clinical Development
Dr. Kamesh Kuchimanchi Ph.D.
Senior Vice President of Regulatory Affairs & Quality Assurance

Important FAQs about investing in OLMA Stock from India :

What is Olema Pharmaceuticals share price today?

Olema Pharmaceuticals share price today is $5.45 as on at the close of the market. Olema Pharmaceuticals share today touched a day high of $5.59 and a low of $5.40.

What is the 52 week high and 52 week low for Olema Pharmaceuticals share?

Olema Pharmaceuticals share touched a 52 week high of $13.93 and a 52 week low of $2.86. Olema Pharmaceuticals stock price today i.e. is closed at $5.45, lower by 60.88% versus the 52 week high.

How to invest in Olema Pharmaceuticals Stock (OLMA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Olema Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Olema Pharmaceuticals Shares that will get you 0.2752 shares as per Olema Pharmaceuticals share price of $5.45 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Olema Pharmaceuticals Stock (OLMA) from India?

Indian investors can start investing in Olema Pharmaceuticals (OLMA) shares with as little as ₹88.286 or $1 (as of August 30, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Olema Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 30, 2025). Based on Olema Pharmaceuticals share’s latest price of $5.45 as on August 30, 2025 at 1:29 am IST, you will get 1.8349 shares of Olema Pharmaceuticals. Learn more about fractional shares .

What are the returns that Olema Pharmaceuticals has given to Indian investors in the last 5 years?

Olema Pharmaceuticals stock has given -88.84% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?